Novartis to use Incyte's database:
This article was originally published in Clinica
Novartis is to use Incyte's LifeSeq gene sequence and expression database for an undisclosed annual fee. Under the multi-year agreement, Incyte could also receive royalties on sales of products developed as a result of its technology and database information.
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.